Latest News and Press Releases
Want to stay updated on the latest news?
-
Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an...
-
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO,...
-
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024...
-
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
-
サンディエゴ発, Dec. 14, 2024 (GLOBE NEWSWIRE) -- アナフィラキシーに至る可能性のあるアレルギー反応から自身を守るための支援を目指すバイオ医薬品企業であるARSファーマシューティカルズ (ARS Pharmaceuticals, Inc.) (NASDAQ: SPRY)...
-
圣地亚哥, Dec. 14, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) 是一家生物制药公司，致力于帮助高风险患者和护理人员更好地保护患者免于可能导致过敏性休克的过敏反应。该公司今天宣布，其在中国、日本和澳大利亚的授权合作伙伴已在各自国家申请批准 2 毫克剂量的 neffy® （肾上腺素鼻喷雾剂）。 2...
-
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
-
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of...
-
Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive...
-
Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration...